{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T15:24:08Z","timestamp":1779377048652,"version":"3.53.1"},"reference-count":47,"publisher":"Pharmaceutical Society of Japan","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological &amp; Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2025,4,12]]},"DOI":"10.1248\/bpb.b24-00726","type":"journal-article","created":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T22:10:01Z","timestamp":1744409401000},"page":"363-371","source":"Crossref","is-referenced-by-count":2,"title":["Piperacillin Exacerbates Vancomycin-Induced Toxicity in Renal Proximal Tubular Cells"],"prefix":"10.1248","volume":"48","author":[{"given":"Shingo","family":"Takada","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy, Graduate School of Pharmaceutical Sciences, Hokkaido University of Science, 15\u20134\u20131 Maeda 7, Teine-ku, Sapporo 006\u20138585, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuya","family":"Takashima","sequence":"additional","affiliation":[{"name":"Department of Pharmacotherapy, Faculty of Pharmaceutical Sciences, Hokkaido University of Science, 15\u20134\u20131 Maeda 7, Teine-ku, Sapporo 006\u20138585, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riku","family":"Shinozaki","sequence":"additional","affiliation":[{"name":"Department of Pharmacotherapy, Faculty of Pharmaceutical Sciences, Hokkaido University of Science, 15\u20134\u20131 Maeda 7, Teine-ku, Sapporo 006\u20138585, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mizuki","family":"Nishisato","sequence":"additional","affiliation":[{"name":"Department of Pharmacotherapy, Faculty of Pharmaceutical Sciences, Hokkaido University of Science, 15\u20134\u20131 Maeda 7, Teine-ku, Sapporo 006\u20138585, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natsuko","family":"Takahashi-Suzuki","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics, Faculty of Pharmaceutical Sciences, Hokkaido University of Science, 15\u20134\u20131 Maeda 7, Teine-ku, Sapporo 006\u20138585, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Takaguri","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Faculty of Pharmaceutical Sciences, Hokkaido University of Science, 15\u20134\u20131 Maeda 7, Teine-ku, Sapporo 006\u20138585, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takehiro","family":"Yamada","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Graduate School of Pharmaceutical Sciences, Hokkaido University of Science, 15\u20134\u20131 Maeda 7, Teine-ku, Sapporo 006\u20138585, Japan"},{"name":"Department of Pharmacotherapy, Faculty of Pharmaceutical Sciences, Hokkaido University of Science, 15\u20134\u20131 Maeda 7, Teine-ku, Sapporo 006\u20138585, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"163","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Khwaja A. KDIGO Clinical Practice Guidelines for acute kidney injury. <i>Nephron Clin. Pract.<\/i>, <b>120<\/b>, c179\u2013c184 (2012).","DOI":"10.1159\/000339789"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Sawhney S, Mitchell M, Marks A, Fluck N, Black C. Long-term prognosis after acute kidney injury (AKI): what is the role of baseline kidney function and recovery? A systematic review. <i>BMJ Open<\/i>, <b>5<\/b>, e006497 (2015).","DOI":"10.1136\/bmjopen-2014-006497"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Susantitaphong P, Cruz DN, Cerda J, Abulfaraj M, Alqahtani F, Koulouridis I, Jaber BL. World incidence of AKI: a meta-analysis. <i>Clin. J. Am. Soc. Nephrol.<\/i>, <b>8<\/b>, 1482\u20131493 (2013).","DOI":"10.2215\/CJN.00710113"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Thongprayoon C, Hansrivijit P, Kovvuru K, Kanduri SR, Torres-Ortiz A, Acharya P, Gonzalez-Suarez ML, Kaewput W, Bathini T, Cheungpasitporn W. Diagnostics, risk factors, treatment and outcomes of acute kidney injury in a new paradigm. <i>J. Clin. Med.<\/i>, <b>9<\/b>, 1104 (2020).","DOI":"10.3390\/jcm9041104"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Perazella MA, Rosner MH. Drug-induced acute kidney injury. <i>Clin. J. Am. Soc. Nephrol.<\/i>, <b>17<\/b>, 1220\u20131233 (2022).","DOI":"10.2215\/CJN.11290821"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Liu C, Yan S, Wang Y, et al. Drug-induced hospital-acquired acute kidney injury in China: a multicenter cross-sectional survey. <i>Kidney Dis.<\/i> (Basel), <b>7<\/b>, 143\u2013155 (2021).","DOI":"10.1159\/000510455"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Filippone EJ, Kraft WK, Farber JL. The nephrotoxicity of vancomycin. <i>Clin. Pharmacol. Ther.<\/i>, <b>102<\/b>, 459\u2013469 (2017).","DOI":"10.1002\/cpt.726"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Arimura Y, Yano T, Hirano M, Sakamoto Y, Egashira N, Oishi R. Mitochondrial superoxide production contributes to vancomycin-induced renal tubular cell apoptosis. <i>Free Radic. Biol. Med.<\/i>, <b>52<\/b>, 1865\u20131873 (2012).","DOI":"10.1016\/j.freeradbiomed.2012.02.038"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Sakamoto Y, Yano T, Hanada Y, Takeshita A, Inagaki F, Masuda S, Matsunaga N, Koyanagi S, Ohdo S. Vancomycin induces reactive oxygen species-dependent apoptosis <i>via<\/i> mitochondrial cardiolipin peroxidation in renal tubular epithelial cells. <i>Eur. J. Pharmacol.<\/i>, <b>800<\/b>, 48\u201356 (2017).","DOI":"10.1016\/j.ejphar.2017.02.025"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Takigawa M, Masutomi H, Kishimoto Y, Shimazaki Y, Hamano Y, Kondo Y, Arai T, Lee J, Ishii T, Mori Y, Ishigami A. Time-dependent alterations of vancomycin-induced nephrotoxicity in mice. <i>Biol. Pharm. Bull.<\/i>, <b>40<\/b>, 975\u2013983 (2017).","DOI":"10.1248\/bpb.b16-00932"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Humanes B, Jado JC, Cama\u00f1o S, L\u00f3pez-Parra V, Torres AM, \u00c1lvarez-Sala LA, Cercenado E, Tejedor A, L\u00e1zaro A. Protective effects of cilastatin against vancomycin-induced nephrotoxicity. <i>BioMed Res. Int.<\/i>, <b>2015<\/b>, 704382 (2015).","DOI":"10.1155\/2015\/704382"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Nolin TD. Vancomycin and the risk of AKI: now clearer than Mississippi mud. <i>Clin. J. Am. Soc. Nephrol.<\/i>, <b>11<\/b>, 2101\u20132103 (2016).","DOI":"10.2215\/CJN.11011016"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Gomes DM, Smotherman C, Birch A, Dupree L, Della Vecchia BJ, Kraemer DF, Jankowski CA. Comparison of acute kidney injury during treatment with vancomycin in combination with piperacillin-tazobactam or cefepime. <i>Pharmacotherapy<\/i>, <b>34<\/b>, 662\u2013669 (2014).","DOI":"10.1002\/phar.1428"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Burgess LD, Drew RH. Comparison of the incidence of vancomycin-induced nephrotoxicity in hospitalized patients with and without concomitant piperacillin-tazobactam. <i>Pharmacotherapy<\/i>, <b>34<\/b>, 670\u2013676 (2014).","DOI":"10.1002\/phar.1442"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Moenster RP, Linneman TW, Finnegan PM, Hand S, Thomas Z, McDonald JR. Acute renal failure associated with vancomycin and <i>\u03b2<\/i>-lactams for the treatment of osteomyelitis in diabetics: piperacillin-tazobactam as compared with cefepime. <i>Clin. Microbiol. Infect.<\/i>, <b>20<\/b>, O384\u2013O389 (2014).","DOI":"10.1111\/1469-0691.12410"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Luther MK, Timbrook TT, Caffrey AR, Dosa D, Lodise TP, LaPlante KL. Vancomycin plus piperacillin-tazobactam and acute kidney injury in adults: a systematic review and meta-analysis. <i>Crit. Care Med.<\/i>, <b>46<\/b>, 12\u201320 (2018).","DOI":"10.1097\/CCM.0000000000002769"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Imai S, Kadomura S, Miyai T, Kashiwagi H, Sato Y, Sugawara M, Takekuma Y. Using Japanese big data to investigate novel factors and their high-risk combinations that affect vancomycin-induced nephrotoxicity. <i>Br. J. Clin. Pharmacol.<\/i>, <b>88<\/b>, 3241\u20133255 (2022).","DOI":"10.1111\/bcp.15252"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Contejean A, Tisseyre M, Canou\u00ef E, Treluyer JM, Kerneis S, Chouchana L. Combination of vancomycin plus piperacillin and risk of acute kidney injury: a worldwide pharmacovigilance database analysis. <i>J. Antimicrob. Chemother.<\/i>, <b>76<\/b>, 1311\u20131314 (2021).","DOI":"10.1093\/jac\/dkab003"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Kadomura S, Takekuma Y, Sato Y, Kawamoto K, Itoh T, Sugawara M. Higher incidence of acute kidney injury in patients treated with piperacillin\/tazobactam than in patients treated with cefepime: a single-center retrospective cohort study. <i>J. Pharm. Health Care Sci.<\/i>, <b>5<\/b>, 13 (2019).","DOI":"10.1186\/s40780-019-0142-6"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Yang J, Ko YS, Lee HY, Fang Y, Oh SW, Kim M-G, Cho WY, Jo S-K. Mechanisms of piperacillin\/tazobactam nephrotoxicity: piperacillin\/tazobactam-induced direct tubular damage in mice. <i>Antibiotics<\/i> (Basel), <b>12<\/b>, 1121 (2023).","DOI":"10.3390\/antibiotics12071121"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Bazargani B, Moghtaderi M. New biomarkers in early diagnosis of acute kidney injury in children. <i>Avicenna J. Med. Biotechnol.<\/i>, <b>14<\/b>, 264\u2013269 (2022).","DOI":"10.18502\/ajmb.v14i4.10478"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Star RA. Treatment of acute renal failure. <i>Kidney Int.<\/i>, <b>54<\/b>, 1817\u20131831 (1998).","DOI":"10.1046\/j.1523-1755.1998.00210.x"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Malhotra R, Siew ED. Biomarkers for the early detection and prognosis of acute kidney injury. <i>Clin. J. Am. Soc. Nephrol.<\/i>, <b>12<\/b>, 149\u2013173 (2017).","DOI":"10.2215\/CJN.01300216"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Schrezenmeier EV, Barasch J, Budde K, Westhoff T, Schmidt-Ott KM. Biomarkers in acute kidney injury\u2014pathophysiological basis and clinical performance. <i>Acta Physiol.<\/i> (Oxf.), <b>219<\/b>, 554\u2013572 (2017).","DOI":"10.1111\/apha.12764"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. <i>J. Immunol. Methods<\/i>, <b>65<\/b>, 55\u201363 (1983).","DOI":"10.1016\/0022-1759(83)90303-4"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Yamada T, Ishikawa S, Ishiguro N, Kobayashi M, Iseki K. Evaluation of daptomycin-induced cellular membrane injury in skeletal muscle. <i>Biol. Pharm. Bull.<\/i>, <b>43<\/b>, 1338\u20131345 (2020).","DOI":"10.1248\/bpb.b20-00217"},{"key":"27","unstructured":"27) Shiba K. Phase I study of tazobactam\/piperacillin in healthy volunteers. <i>Jpn. J. Chemother<\/i>., <b>58<\/b> (S-1): 1\u201310 (2010)."},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Hashimoto N, Kimura T, Hamada Y, Niwa T, Hanai Y, Chuma M, Fujii S, Matsumoto K, Shigemi A, Kawamura H, Takahashi Y, Takesue Y. Candidates for area under the concentration-time curve (AUC)-guided dosing and risk reduction based on analyses of risk factors associated with nephrotoxicity in vancomycin-treated patients. <i>J. Glob. Antimicrob. Resist.<\/i>, <b>27<\/b>, 12\u201319 (2021).","DOI":"10.1016\/j.jgar.2021.07.018"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Matsumoto K, Oda K, Shoji K, Hanai Y, Takahashi Y, Fujii S, Hamada Y, Kimura T, Mayumi T, Ueda T, Nakajima K, Takesue Y. Clinical Practice Guidelines for therapeutic drug monitoring of vancomycin in the framework of model-informed precision dosing: a consensus review by the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring. <i>Pharmaceutics<\/i>, <b>14<\/b>, 489 (2022).","DOI":"10.3390\/pharmaceutics14030489"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Hammond DA, Smith MN, Li C, Hayes SM, Lusardi K, Bookstaver PB. Systematic review and metaanalysis of acute kidney injury associated with concomitant vancomycin and piperacillin\/tazobactam. <i>Clin. Infect. Dis.<\/i>, <b>64<\/b>, 666\u2013674 (2017).","DOI":"10.1093\/cid\/ciw811"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Xu W, Mao Z, Zhao B, Ni T, Deng S, Yu P, He J, Mao E. Vitamin C attenuates vancomycin induced nephrotoxicity through the reduction of oxidative stress and inflammation in HK-2 cells. <i>Ann. Palliat. Med.<\/i>, <b>10<\/b>, 1748\u20131754 (2021).","DOI":"10.21037\/apm-20-694"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Pais GM, Liu J, Avedissian SN, Hiner D, Xanthos T, Chalkias A, d\u2019Aloja E, Locci E, Gilchrist A, Prozialeck WC, Rhodes NJ, Lodise TP, Fitzgerald JC, Downes KJ, Zuppa AF, Scheetz MH. Lack of synergistic nephrotoxicity between vancomycin and piperacillin\/tazobactam in a rat model and a confirmatory cellular model. <i>J. Antimicrob. Chemother.<\/i>, <b>75<\/b>, 1228\u20131236 (2020).","DOI":"10.1093\/jac\/dkz563"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) C\u00f4t\u00e9 JM, Desjardins M, Murray PT. Does vancomycin-piperacillin-tazobactam cause pseudo-AKI, true nephrotoxicity, or both? <i>Chest<\/i>, <b>164<\/b>, 273\u2013274 (2023).","DOI":"10.1016\/j.chest.2023.05.009"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) Karino F, Nishimura N, Ishihara N, Moriyama H, Miura K, Hamaguchi S, Sutani A, Kuraki T, Ikawa K, Morikawa N. Nephrotoxicity induced by piperacillin-tazobactam in late elderly Japanese patients with nursing and healthcare associated pneumonia. <i>Biol. Pharm. Bull.<\/i>, <b>37<\/b>, 1971\u20131976 (2014).","DOI":"10.1248\/bpb.b14-00362"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35) Lee JD, Heintz BH, Mosher HJ, Livorsi DJ, Egge JA, Lund BC. Risk of acute kidney injury and Clostridioides difficile infection with piperacillin\/tazobactam, cefepime, and meropenem with or without vancomycin. <i>Clin. Infect. Dis.<\/i>, <b>73<\/b>, e1579\u2013e1586 (2021).","DOI":"10.1093\/cid\/ciaa1902"},{"key":"36","unstructured":"36) Igarashi K, Hatano S, Uda H, Tamai I, Kawahara M. Frequency of acute renal dysfunction caused by tazobactam\/piperacillin and serum concentrations of tazobactam\/piperacillin in patients with acute renal failure. <i>The Japanese Journal of Therapeutic Drug Monitoring<\/i>, <b>31<\/b>, 117\u2013122 (2014)."},{"key":"37","doi-asserted-by":"crossref","unstructured":"37) Miano TA, Hennessy S, Yang W, Dunn TG, Weisman AR, Oniyide O, Agyekum RS, Turner AP, Ittner CAG, Anderson BJ, Wilson FP, Townsend R, Reilly JP, Giannini HM, Cosgriff CV, Jones TK, Meyer NJ, Shashaty MGS. Association of vancomycin plus piperacillin-tazobactam with early changes in creatinine <i>versus<\/i> cystatin C in critically ill adults: a prospective cohort study. <i>Intensive Care Med.<\/i>, <b>48<\/b>, 1144\u20131155 (2022).","DOI":"10.1007\/s00134-022-06811-0"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38) Mayr HO, Regenbrecht N, Mayr MF, Riedel B, Hart ML, Schmal H, Seidenstuecker M. Effect of vancomycin, gentamicin and clindamycin on cartilage cells in vitro. <i>Biomedicines<\/i>, <b>11<\/b>, 3143 (2023).","DOI":"10.3390\/biomedicines11123143"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39) Li H, Yang Q, Gui M, Ding L, Yang L, Sun H, Li Z. Changes of renal transporters in the kinetic process of VCM-induced nephrotoxicity in mice. <i>Toxicol. Res.<\/i> (Camb.), <b>10<\/b>, 687\u2013695 (2021).","DOI":"10.1093\/toxres\/tfab048"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40) Uchida Y, Kamiie J, Ohtsuki S, Terasaki T. Multichannel liquid chromatography-tandem mass spectrometry cocktail method for comprehensive substrate characterization of multidrug resistance-associated protein 4 transporter. <i>Pharm. Res.<\/i>, <b>24<\/b>, 2281\u20132296 (2007).","DOI":"10.1007\/s11095-007-9453-7"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41) Sampaio de Souza Garms D, Cardoso Eid KZ, Burdmann EA, Mar\u00e7al LJ, Anton\u00e2ngelo L, Dos Santos A, Ponce D. The role of urinary biomarkers as diagnostic and prognostic predictors of acute kidney injury associated with vancomycin. <i>Front. Pharmacol.<\/i>, <b>12<\/b>, 705636 (2021).","DOI":"10.3389\/fphar.2021.705636"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42) Westhoff JH, Seibert FS, Waldherr S, Bauer F, T\u00f6nshoff B, Fichtner A, Westhoff TH. Urinary calprotectin, kidney injury molecule-1, and neutrophil gelatinase-associated lipocalin for the prediction of adverse outcome in pediatric acute kidney injury. <i>Eur. J. Pediatr.<\/i>, <b>176<\/b>, 745\u2013755 (2017).","DOI":"10.1007\/s00431-017-2907-y"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43) Sohn SJ, Kim SY, Kim HS, Chun YJ, Han SY, Kim SH, Moon A. <i>In vitro<\/i> evaluation of biomarkers for cisplatin-induced nephrotoxicity using HK-2 human kidney epithelial cells. <i>Toxicol. Lett.<\/i>, <b>217<\/b>, 235\u2013242 (2013).","DOI":"10.1016\/j.toxlet.2012.12.015"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44) Zhang Z, Cai CX. Kidney injury molecule-1 (KIM-1) mediates renal epithelial cell repair <i>via<\/i> ERK MAPK signaling pathway. <i>Mol. Cell. Biochem.<\/i>, <b>416<\/b>, 109\u2013116 (2016).","DOI":"10.1007\/s11010-016-2700-7"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45) Kanda J, Mori K, Kawabata H, Kuwabara T, Mori KP, Imamaki H, Kasahara M, Yokoi H, Mizumoto C, Thoennissen NH, Koeffler HP, Barasch J, Takaori-Kondo A, Mukoyama M, Nakao K. An AKI biomarker lipocalin 2 in the blood derives from the kidney in renal injury but from neutrophils in normal and infected conditions. <i>Clin. Exp. Nephrol.<\/i>, <b>19<\/b>, 99\u2013106 (2015).","DOI":"10.1007\/s10157-014-0952-7"},{"key":"46","unstructured":"46) Nakajima M, Katagiri K, Oguma T. Phase I studies on vancomycin hydrochloride for injection. <i>Chemotherapy<\/i>, <b>40<\/b>, 210\u2013214 (1992)."},{"key":"47","doi-asserted-by":"crossref","unstructured":"47) Wen S, Wang C, Duan Y, Huo X, Meng Q, Liu Z, Yang S, Zhu Y, Sun H, Ma X, Yang S, Liu K. OAT1 and OAT3 also mediate the drug-drug interaction between piperacillin and tazobactam. <i>Int. J. Pharm.<\/i>, <b>537<\/b>, 172\u2013182 (2018).","DOI":"10.1016\/j.ijpharm.2017.12.037"}],"container-title":["Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/48\/4\/48_b24-00726\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T03:42:30Z","timestamp":1744429350000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/48\/4\/48_b24-00726\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,12]]},"references-count":47,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b24-00726","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,12]]},"article-number":"b24-00726"}}